10:01 AM EST - Bausch Health Companies Inc. : Today announced positive topline results from the Company's Phase 2 study evaluating Amiselimod, an investigative S1P antagonist, for the treatment of ulcerative colitis. Bausch Health Companies Inc.
shares T.BHC are trading up $0.07 at $9.76.
